Please assess the completion status of the following clinical trial:

Trial Title: Rituximab Treatment in Sjogren's Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Stimulated whole saliva secretion ≥ 0,15 ml/min~* Male or female \> 18 years~* Primary SS according to the revised European - U.S. criteria(22)~* Positive autoantibodies (IgM-Rf \> 10 and SS-A and/or SS-B)~* Parotid gland biopsy (paraffine material and fresh frozen tissue) with characteristic features of SS performed at time of inclusion (no longer than 12 months ago)~* Use of reliable method of contraception during the study~* Written informed consent~Exclusion Criteria:~* The presence of any other connective tissue disease~* Preceding treatment with anti-TNF or other monoclonal antibodies~* Use of prednisone, hydroxychloroquine less than 1 month ago~* Use of MTX, cyclophosphamide, cyclosporin, azathioprine and other DMARDS less than 0,5 year ago~* Serum creatine \> 2.8 mg/dl (250 micromol/l)~* ASAT or ALAT outside 1.5 x upper normal range of the laboratory~* Hb \< 9 g/dl (5.6 mmol/l) for males and 8.5 g/dl (5.3 mmol/l) for females~* Neutrophil granulocytes less than 0.5 x 109/l~* Platelet count less then 50 x 109/l~* Positive pregnancy test or breast-feeding~* History of alcohol or drug abuse~* Serious infections~* Underlying cardiac, pulmonary, metabolic, renal or gastrointestinal conditions, chronic or latent infectious diseases or immune deficiency which places the patient at an unacceptable risk for participation in the study~* History of any malignancy with the exception of completely resected basal cell carcinoma of the skin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).